Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
A new variant of SARS-CoV-2, named PJ.2.1, was first identified in Ontario, Canada in May…
Belonging: A Journey of Love, a memoir written by Congress leader Sonia Gandhi, will be…
The United States will become the first nation to fully opt out of participating in…
A group of US lawmakers, led by Rep Grace Meng, have re-introduced the Diwali Day…
Pandit Manilal Nag, a celebrated sitar maestro and one of the foremost exponents of the…
The 31st Conference of the Parties (COP31) to the United Nations Framework Convention on Climate…